全文获取类型
收费全文 | 139871篇 |
免费 | 8435篇 |
国内免费 | 2469篇 |
专业分类
耳鼻咽喉 | 1021篇 |
儿科学 | 2899篇 |
妇产科学 | 2931篇 |
基础医学 | 15548篇 |
口腔科学 | 4538篇 |
临床医学 | 12563篇 |
内科学 | 25928篇 |
皮肤病学 | 1899篇 |
神经病学 | 8258篇 |
特种医学 | 2816篇 |
外国民族医学 | 30篇 |
外科学 | 17860篇 |
综合类 | 14399篇 |
现状与发展 | 14篇 |
一般理论 | 5篇 |
预防医学 | 12359篇 |
眼科学 | 1550篇 |
药学 | 12428篇 |
49篇 | |
中国医学 | 4647篇 |
肿瘤学 | 9033篇 |
出版年
2023年 | 1473篇 |
2022年 | 3284篇 |
2021年 | 5019篇 |
2020年 | 3706篇 |
2019年 | 7460篇 |
2018年 | 7666篇 |
2017年 | 5811篇 |
2016年 | 3792篇 |
2015年 | 3876篇 |
2014年 | 6336篇 |
2013年 | 7341篇 |
2012年 | 5932篇 |
2011年 | 6576篇 |
2010年 | 5250篇 |
2009年 | 4607篇 |
2008年 | 4878篇 |
2007年 | 4739篇 |
2006年 | 4299篇 |
2005年 | 3654篇 |
2004年 | 3064篇 |
2003年 | 2657篇 |
2002年 | 2137篇 |
2001年 | 2038篇 |
2000年 | 1714篇 |
1999年 | 1476篇 |
1998年 | 1153篇 |
1997年 | 1111篇 |
1996年 | 999篇 |
1995年 | 896篇 |
1994年 | 843篇 |
1993年 | 712篇 |
1992年 | 696篇 |
1991年 | 634篇 |
1990年 | 556篇 |
1989年 | 484篇 |
1988年 | 383篇 |
1987年 | 380篇 |
1985年 | 3220篇 |
1984年 | 3679篇 |
1983年 | 3053篇 |
1982年 | 3599篇 |
1981年 | 3246篇 |
1980年 | 2707篇 |
1979年 | 2658篇 |
1978年 | 2197篇 |
1977年 | 1664篇 |
1976年 | 2087篇 |
1975年 | 1588篇 |
1974年 | 1377篇 |
1973年 | 1321篇 |
排序方式: 共有10000条查询结果,搜索用时 78 毫秒
21.
22.
Michelle E. Wilson Charles Kim Jacqueline Carrasco 《Orbit (Amsterdam, Netherlands)》2016,35(5):288-291
A 48-year-old smoker with a history of hyperthyroidism treated 10 years prior to presentation with radioactive iodine ablation of the thyroid gland presented to his ophthalmologist with a 2-week history of transient loss of vision in the right eye occurring for 1 to 2 hours each morning. He denied ocular pain, diplopia or change in the prominence of one or both eyes. Examination revealed 2 mm of relative proptosis on the right, bilateral temporal flare and lower lid retraction. There was minimal upper lid retraction and no evidence of lid lag. Ocular motility was full. Dilated fundoscopic examination revealed bilateral optic nerve edema, right more than left. CT of the orbit demonstrated enlargement of the extraocular muscles bilaterally with marked enlargement of the right medial rectus and left inferior rectus muscles resulting in crowding at the orbital apex bilaterally. Laboratory testing revealed the patient to be hyperthyroid. The patient was treated with high dose oral steroids followed by orbital radiation. Hyperthyroidism was managed by the patient’s primary care physician. Visual symptoms rapidly improved with oral steroids and orbital radiation. Optic nerve edema completely resolved. Repeat CT imaging demonstrated a reduction in the enlargement of the extraocular muscles with relief of bilateral optic nerve compression. 相似文献
23.
《Neuro-Chirurgie》2022,68(3):262-266
BackgroundThe prognosis for patients with recurrent glioblastoma (GBM) is dismal, and the question of repeat surgery at time of recurrence is common. Re-operation in the management of these patients remains controversial, as there is no randomized evidence of benefit. An all-inclusive pragmatic care trial is needed to evaluate the role of repeat resection.Methods3rGBM is a multicenter, pragmatic, prospective, parallel-group randomized care trial, with 1:1 allocation to repeat resection or standard care with no repeat resection. To test the hypothesis that repeat resection can improve overall survival by at least 3 months (from 6 to 9 months), 250 adult patients with prior resection of pathology-proven glioblastoma for whom the attending surgeon believes repeat resection may improve quality survival will be enrolled. A surrogate measure of quality of life, the number of days outside of hospital/nursing/palliative care facility, will also be compared. Centers are invited to participate without financial compensation and without contracts. Clinicians may apply to local authorities to approve an investigator-led in-house trial, using a common protocol, web-based randomization platform, and simple standardized case report forms.DiscussionThe 3rGBM trial is a modern transparent care research framework with no additional risks, tests, or visits other than what patients would encounter in normal care. The burden of proof remains on repeat surgical management of recurrent GBM, because this management has yet to be shown beneficial. The trial is designed to help patients and surgeons manage the uncertainty regarding optimal care.Clinical Trial Registrationhttp://www.clinicaltrials.gov. Unique identifier: NCT04838782. 相似文献
24.
����һ���� Ȫ 《中国实用外科杂志》2019,39(3):223-225
妊娠期甲状腺癌的诊治是目前甲状腺疾病诊治的热点和难点问题之一。妊娠期发现甲状腺癌对临床医生和孕妇都是一个极大的挑战,应通过多学科协作,尽快明确诊断,全面、合理的评估孕妇和胎儿的情况,选择最合适的治疗和随诊方式,避免对孕妇和胎儿产生副反应,维持正常孕期,获得最佳的治疗效果。 相似文献
25.
JeongYun Choi Haeseung Lee EunJi Kwon HyeonJoon Kong OkSeon Kwon HyukJin Cha 《Molecular oncology》2021,15(2):679
The acquisition of chemoresistance remains a major cause of cancer mortality due to the limited accessibility of targeted or immune therapies. However, given that severe alterations of molecular features during epithelial‐to‐mesenchymal transition (EMT) lead to acquired chemoresistance, emerging studies have focused on identifying targetable drivers associated with acquired chemoresistance. Particularly, AXL, a key receptor tyrosine kinase that confers resistance against targets and chemotherapeutics, is highly expressed in mesenchymal cancer cells. However, the underlying mechanism of AXL induction in mesenchymal cancer cells is poorly understood. Our study revealed that the YAP signature, which was highly enriched in mesenchymal‐type lung cancer, was closely correlated to AXL expression in 181 lung cancer cell lines. Moreover, using isogenic lung cancer cell pairs, we also found that doxorubicin treatment induced YAP nuclear translocation in mesenchymal‐type lung cancer cells to induce AXL expression. Additionally, the concurrent activation of TGFβ signaling coordinated YAP‐dependent AXL expression through SMAD4. These data suggest that crosstalk between YAP and the TGFβ/SMAD axis upon treatment with chemotherapeutics might be a promising target to improve chemosensitivity in mesenchymal‐type lung cancer.
Abbreviations
- AUC
- area under the curve
- AXL
- AXL receptor tyrosine kinase
- BCL2
- B‐cell lymphoma 2
- CTD2
- cancer target discovery and development
- CTGF
- connective tissue growth factor
- DEG
- differentially expressed genes
- DOXO
- doxorubicin
- EMT
- epithelial–mesenchymal transition
- Eto
- etoposide
- FDA
- Food and Drug Administration
- ITGB3
- integrin beta‐3
- MAPK
- mitogen‐activated protein kinase
- MMP2
- matrix metalloproteinase‐2
- MMP9
- matrix metalloproteinase‐9
- mRNA
- messenger RNA
- NF‐κB
- nuclear factor kappa‐light‐chain‐enhancer of activated B cells
- SBE
- SMAD binding element
- SERPINE1
- serpin family E member 1
- siRNA
- small interfering RNA
- ssGSEA
- single‐sample gene set enrichment analysis
- TCGA
- The Cancer Genome Atlas
- TGFβ
- transforming growth factor beta
- YAP
- Yes‐associated protein
- YAP8SA
- mutants of inhibitory phosphorylation site at eight serine to Alanine of YAP
- ZEB1
- zinc finger E‐box binding homeobox 1
- ZEB2
- zinc finger E‐box‐binding homeobox 2
26.
27.
目的:分析2010年至2018年甲状腺结节相关SCI论文,并建模进行定性与定量分析。方法:利用文献计量学中的引文分析、共被引分析、数据可视化、聚类分析等方法,使用CiteSpace分析工具,分析来源于Web of ScienceTM核心合集数据库中有关论文的出版情况、国家、机构、作者、知识基础与研究热点。结果:到2018年10月31日截止,研究了4 618篇论文。发表论文数:美国在国家/地区中排名第一,延世大学在研究机构中排名第一,Kwak JY在所有作者中排名第一。从2010年开始,每年发表的论文数量都在稳步增长,有相当多的论文发表在如《新英格兰杂志》、《THYROID》、《JAMA》、《CELL》等高影响因子的期刊上。甲状腺结节的SCI论文参考文献聚类为6类,分别是papillary-like nuclear feature、current statu、radiofrequency ablation、ultrasound elastography、goiter area、data system。代表研究前沿的关键词是meta-analysis、recommendation、thyroid carcinoma、shear wave elastography与bethesda system。结论:本文通过对国际上甲状腺结节的研究基础、研究热点的分析,阐述了甲状腺结节的研究趋势,为我国医学工作者的研究提供参考。 相似文献
28.
29.
30.
《Journal of vascular and interventional radiology : JVIR》2020,31(1):25-34
PurposeTo investigate the safety of yttrium-90 radioembolization in combination with checkpoint inhibitor immunotherapy for the treatment of hepatocellular carcinoma (HCC).Materials and MethodsThis single-center retrospective study included 26 consecutive patients with HCC who received checkpoint inhibitor immunotherapy within 90 days of radioembolization from April 2015 to May 2018. Patients had preserved liver function (Child-Pugh scores A–B7) and either advanced HCC due to macrovascular invasion or limited extrahepatic disease (21 patients) or aggressive intermediate stage HCC that resulted in earlier incorporation of systemic immunotherapy (5 patients). Clinical documentation, laboratory results, and imaging results at 1- and 3-month follow-up intervals were reviewed to assess treatment-related adverse events and treatment responses.ResultsThe median follow-up period after radioembolization was 7.8 months (95% confidence interval [CI], 5.6–11.8). There were no early (30-day) mortality or grades 3/4 hepatobiliary or immunotherapy-related toxicities. Delayed grades 3/4 hepatobiliary toxicities (1–3 months) occurred in 2 patients in the setting of HCC disease progression. One patient developed pneumonitis. The median overall survival from first immunotherapy was 17.2 months (95% CI, 10.9–23.4). The median overall survival from first radioembolization was 16.5 months (95% CI, 6.6–26.4). From first radioembolization, time to tumor progression was 5.7 months (95% CI, 4.2–7.2), and progression-free survival was 5.7 months (95% CI, 4.3–7.1).ConclusionsRadioembolization combined with checkpoint inhibitor immunotherapy in cases of HCC appears to be safe and causes limited treatment-related toxicity. Future prospective studies are needed to identify the optimal combination treatment protocols and evaluate the efficacy of combination therapy. 相似文献